Fig. 6: Structure of the 1-2C and 3-2E TCRs bound to KRAS-G12V-9/HLA-A*11:01.
From: KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
a–d Structure of 1-2C bound to KRAS-G12V-9/HLA-A*11:01. a Overall structures of the 1-2C TCR in complex with the KRAS-G12V-9/HLA-A*11:01 pHLA ligand. The 1-2C TCR is shown in cyan (α chain) and green (β chain). HLA-A*11:01 is shown in pale yellow (heavy chain) and blue (β2m), and the peptide is shown in pink (KRAS-G12V-9). b The footprints of 1-2C on the KRAS-G12V-9/HLA-A*11:01 pHLA complex. The three CDRαs of 1-2C are represented as ribbons in cyan, while the three CDRβs are in green. HLA-A*11:01 is depicted as a surface in gray and the KRAS-G12V-9 peptide is presented as a surface in pink. c The distribution (%) of HLA-A*11:01 and KRAS-G12V-9 peptide for the recognition of 1-2C TCR. d The distribution (%) of the CDR loops of 1-2C for the interaction with HLA-A*11:01. e–h The binding of the 3-2E TCR with the KRAS-G12V-9 peptide is presented similar to that of 1-2C in (a–d). i Comparison of the CDRs of the 3-2E TCR to that of 1-2C when bound with KRAS-G12V-9/HLA-A*11:01. The CDRs of the 3-2E were colored in gray, whereas the three CDRα of 1-2C are presented in cyan and the three CDRβ in green. j The binding orientation of 1-2C and 3-2E TCR with KRAS-G12V-9/HLA-A*11:01 pHLA. k, l The distribution (%) of the CDR loops of 1-2C for the interaction with the KRAS-G12V-9 peptide.
